A practical reference on GLP-1 receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-13. Anything still debated is marked as such rather than presented as settled.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
=== Chemotherapy metabolite === Cyclophosphamide and ifosfamide treatment results in the production of acrolein. Acrolein produced during cyclophosphamide treatment collects in the urinary bladder and if untreated can cause hemorrhagic cystitis.
DNA barcoding A method of taxonomic identification in which short DNA sequences from one or more specific genes are isolated from unidentified samples and then aligned with a genomic reference library in order to uniquely identify the species or other taxon from which the samples originated. The sequences used in the comparison are chosen carefully from genes that are both widely conserved and that show greater variation between species than within species, e.g. the cytochrome c oxidase gene for eukaryotes or certain ribosomal RNA genes for prokaryotes. These genes are present in nearly all living organisms but tend to evolve different mutations in different species, such that a unique sequence variant can often be linked to one particular species, effectively creating a unique identifier akin to a retail barcode. DNA barcoding allows unknown specimens to be identified from otherwise indistinct tissues or body parts, where identification by morphology would be difficult or impossible, and the library of organismal barcodes is now comprehensive enough that even organisms previously unknown to science can often be phylogenetically classified with confidence. The simultaneous identification of multiple different species from a mixed sample is known as metabarcoding.
Another electrophysiological measurement that can be made is fusion event duration in a nystatin-ergosterol based system. Fusions are measured while the voltage is held constant, and is characterized by a spike in the current that then returns to the baseline current as the nystatin channels close. When present in smaller concentrations, nystatin momentarily forms pores that allows a vesicle fusion to occur more easily; that fusion then interrupts the pore stability and the nystatin and ergosterol disperse from each other. Conversely, researchers have found that the half-life of these nystatin pores increase with an increased dosage level of nystatin to the membrane systems. This indicates a lower energy of both the lipid membrane and the ionophores when there is a higher concentration of nystatin.
== Criticism == The concepts of EMT and MET has been criticized for not having clearly defined start and end states, specific molecular changes universal across the categories, and/or over-interpreting the phenotype change in cancer cells.
== SASP Index == A SASP index composed of 22 SASP factors has been used to evaluate treatment outcomes of late life depression. Higher SASP index scores corresponded to increased incidence of treatment failure, whereas no individual SASP factors were associated with treatment failure.
Sources: en.wikipedia.org
COVID-19 in the UK: Lockdown Files: The Telegraph publishes messages that are reported to have been exchanged between Allan Nixon, a parliamentary Advisor and Matt Hancock from November 2020 in which they discuss threatening to cancel projects in MPs' constituencies if MPs do not support the local lockdown tiers legislation. It is also reported that as part of a strategy aimed at trying to stop MPs from rebelling against the legislation, party whips compiled a spreadsheet of 95 MPs who disagreed with this policy and the reasons for them disagreeing; these related to lack of parliamentary scrutiny, economic harm, harms to hospital, absence of cost benefit analysis and the policy being "unconservative". 7 March A cold snap from the Arctic hits the UK, causing snowfall in Scotland and parts of northern England. Two coal fire power stations are also reactivated amid concerns about the strain the cold snap could cause on the National Grid. Home Secretary Suella Braverman introduces the Illegal Migration Bill into the House of Commons, which is designed to stop migrants arriving in the UK by boat. The legislation proposes to detain and remove those from the UK who arrive by illegal means, as well as blocking them from returning. COVID-19 in the UK: The Joint Committee on Vaccination and Immunisation announces that everyone over 75, care-home residents and anyone considered to be extremely vulnerable aged five and over will be offered a spring COVID-19 booster vaccine.
The Edman degradation is a very important reaction for protein sequencing, because it allows the ordered amino acid composition of a protein to be discovered. Automated Edman sequencers are now in widespread use, and are able to sequence peptides up to approximately 50 amino acids long. A reaction scheme for sequencing a protein by the Edman degradation follows; some of the steps are elaborated on subsequently.
=== Relative biological effectiveness === After World War II, the concept of tolerance dose was replaced by that of maximum permissible dose and the concept of relative biological effectiveness was introduced. The limit was set in 1956 by the National Council on Radiation Protection & Measurements (NCRP) and the International Commission on Radiological Protection (ICRP) at 5 rem (50 mSv) per year for radiation workers and 0.5 rem per year for the general population. The unit Rem as a physical measure of radiation dose (from the English roentgen equivalent in man) was replaced by the unit Sv (sievert) in 1978. This was due to the advent of nuclear energy and its associated dangers. Prior to 1991, the equivalent dose was used both as a measure of dose and as a term for the body dose that determines the course and survival of radiation sickness. ICRP Publication 60 introduced the radiation weighting factor
The IUPAC nomenclature (systematic way of naming compounds) for alkanes is based on identifying hydrocarbon chains. Unbranched, saturated hydrocarbon chains are named systematically with a Greek numerical prefix denoting the number of carbons and the suffix "-ane". In 1866, August Wilhelm von Hofmann suggested systematizing nomenclature by using the whole sequence of vowels a, e, i, o and u to create suffixes -ane, -ene, -ine (or -yne), -one, -une, for the hydrocarbons CnH2n+2, CnH2n, CnH2n−2, CnH2n−4, CnH2n−6. In modern nomenclature, the first three specifically name hydrocarbons with single, double and triple bonds; while "-one" now represents a ketone.
Sources: en.wikipedia.org
4 September: Immigration Minister Erica Stanford confirms that the Government will introduce legislation to make it easier to deport criminals holding permanent residency visas. Carter Holt Harvey confirms plans to close down its Eves Valley sawmill in Tasman District by late November 2025, affecting over 140 jobs. Mayor of Tasman Tim King and Mayor of Nelson Nick Smith had appealed to the forestry company to delay the closure in order to clear fallen trees and vegetation caused by the Winter 2025 New Zealand floods. The New Zealand Police drop sexual misconduct criminal charges against former Deputy Police Commissioner Jevon McSkimming after an independent barrister deemed the evidence as insufficient to meeting the prosecution threshold. He still faces charges of possession of objectionable material. 5 September: Green Party MP Benjamin Doyle announces they would be resigning from Parliament effective 3 October, citing safety concerns. The Sealord Group proposes closing its coated fish factory in Nelson, New Zealand, potentially affecting 79 jobs. The Association of Salaried Medical Specialists rejects Health Minister Simeon Brown's request that the union enter into binding arbitration with Te Whatu Ora (Health New Zealand). Māori Queen Nga wai hono i te po announces two economic initiatives: namely a summit to develop economic opportunities for Māori and a seed investment fund supported by Māori entities. Thunderstorms and strong winds disrupt 28 flights at Wellington International Airport and lead to the closure of New Zealand State Highway 2.
1848: American astronomer Maria Mitchell became the first woman elected to the American Academy of Arts and Sciences; she had discovered a new comet the year before. 1848–1849: English scientist Mary Anne Whitby, a pioneer in western silkworm cultivation, collaborated with Charles Darwin in researching the hereditary qualities of silkworms. 1850: The American Association for the Advancement of Sciences accepted its first women members: astronomer Maria Mitchell, entomologist Margaretta Morris, and science educator Almira Hart Lincoln Phelps.
== Regulations and management == These are tactics and methods that aim to remediate the effects of certain, or all, CEC by preventing movement throughout the environment, or limiting their concentrations in certain environmental systems. It is particularly important to ensure that water treatment approaches do not simply move contaminants from effluent to sludge given the potential for sludge to be spread to land providing an alternative route to entering the environment.
== Personal life == Carrey has depression and took Prozac to combat the symptoms for years. He later said that he no longer takes medications of any kind and abstains from coffee, alcohol, and drugs. He received U.S. citizenship in October 2004 and remains a dual citizen of the United States and his native Canada. Carrey owns various properties in Los Angeles and has lived in Brentwood since 1994. In November 2022, the Russian Ministry of Foreign Affairs banned 100 Canadians, including Carrey, from entering Russia as a reciprocity for the international sanctions which had been introduced due to the 2022 Russian invasion of Ukraine.
14 October – David Lammy becomes the first UK Foreign Secretary to attend a meeting of EU foreign ministers since Brexit as part of Labour's wish to "reset" the UK's relationship with the EU. Monarchists in Australia have criticised a decision by the country's state premieres to be absent from a reception held by Charles III when he visits the country later in the month, describing it as a snub. 16 October – The Assisted Dying Bill is introduced into Parliament, criticised by Archbishop of Canterbury Justin Welby as "dangerous" and a "slippery slope". 17 October – Former Conservative MP Craig Mackinlay is formally introduced into the House of Lords as Lord Mackinlay of Richborough. Now affectionately known as the 'bionic lord', he is the first quadruple amputee to sit in the Lords. 2024 Conservative Party leadership election: Conservative Party leadership candidates Robert Jenrick and Kemi Badenoch take part in a leadership debate on GB News, but Badenoch has turned down an invitation to take part in a Question Time special on BBC One, and a planned online debate organised by The Sun. 18 October – King Charles III and Queen Camilla arrive in Australia for their royal tour, Charles's first visit to the country since becoming King. 10 Downing Street says there will be no apology for the UK's role in the transatlantic slave trade when Charles III and Starmer attend the Commonwealth summit in Samoa. Former Daily Record editor Murray Foote announces he is standing down as chief executive of the SNP after 14 months in the post.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.